Citations

Clear

3042 citation(s) found for "Kumar, S".

Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).
Tandon, Nidhi , Lacy, Martha Q. , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Sidana, Surbhi , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8045-8045

10.1200/jco.2018.36.15_suppl.8045 Get It

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
Tschautscher, Marcella , Lacy, Martha Q. , Hayman, Suzanne R. , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Zeldenrust, Steven R., Lust, John A., Kapoor, Prashant , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Rajkumar, S. Vincent , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8030-8030

10.1200/jco.2018.36.15_suppl.8030 Get It

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Stadtmauer, Edward A. , Monohan, Gregory, Kovacsovics, Tibor , Burwick, Nicholas , Mobasher, Mehrdad, Freise, Kevin J. , Munasinghe, Wijith, Cordero, Jaclyn, Morris, Lura, Maciag, Paulo , Bueno, Orlando F. , Kumar, Shaji , Costa, Luciano J. , Morgan, Gareth J. , Jakubowiak, Andrzej , Ross, Jeremy A. , Pesko, John Carl

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8004-8004

10.1200/jco.2018.36.15_suppl.8004 Get It

Efficacy of up-front hematopoietic cell transplantation in peripheral t-cell lymphoma, not otherwise specified (PTCL-NOS): A National Cancer Database analysis.
Dholaria, Bhagirathbhai , Ayala, Ernesto , Jain, M., Sokol, Lubomir , Hussaini, Mohammad , Kharfan‐Dabaja, Mohamed A. , Dholaria, Bhagirathbhai R , Kumar, Ambuj , Sokol, Lubomir , Chavez, Julio C , Nishihori, Taiga

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7578-7578

10.1200/jco.2018.36.15_suppl.7578 Get It

Predictors of disease progression in smoldering Waldenström macroglobulinemia.
Zanwar, Saurabh , Abeykoon, Jithma P. , Ansell, Stephen M. , Kumar, Shaji , Lacy, Martha Q. , Nowakowski, Grzegorz S. , Kourelis, Taxiarchis , Kyle, Robert A. , Kapoor, Prashant , Dispenzieri, Angela , Witzig, Thomas E. , Buadi, Francis K. , Dingli, David , Leung, Nelson , Rajkumar, S. Vincent , Go, Ronald S. , Habermann, Thomas M. , Lin, Yi , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7571-7571

10.1200/jco.2018.36.15_suppl.7571 Get It

Patient-reported outcomes, emoji, and activity measured on the Apple Watch in cancer patients.
Thompson, Carrie A. , Yost, Kathleen J. , Bartz, Alicia, Ruddy, Kathryn J. , Uhm, Joon H. , Warsame, Rahma , Novotny, Paul J. , Sloan, Jeffrey A., Kumar, Amanika , Stan, Daniela , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6501-6501

10.1200/jco.2018.36.15_suppl.6501 Get It

A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Cornell, Robert F. , Bishop, Michael R. , Larson, Sarah , Borrello, Ivan , Kumar, Shaji , Rossi, John M. , Thomrongsith, Lisa, Xue, Allen , Roberts, Zachary , Locke, Frederick L. , Bishop, Michael Russell , Orlowski, Robert Z. , Giralt, Sergio , Nooka, Ajay K. , Raje, Noopur

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS3103-TPS3103

10.1200/jco.2018.36.15_suppl.tps3103 Get It

Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.
Kumar, Shaji , Kourelis, Taxiarchis , Lacy, Martha Q. , Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Hwa, Yi L. , Kyle, Robert A. , Warsame, Rahma , Aljama, Mohammed A. , Sidiqi, M Hasib , Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson I. , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Leung, Nelson , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8023-8023

10.1200/jco.2018.36.15_suppl.8023 Get It

A Validated Score Predicts Acute Kidney Injury and Survival in Patients With Alcoholic Hepatitis
Ravi, Sujan, Cruz‐Lemini, M. , Altamirano, José , Simonetto, Douglas A. , Maiwall, Rakhi , Axley, Page , Richardson, Taylor, Desai, Vivek, Cabezas, Joaquín , Vargas, Vı́ctor , Kamath, Patrick S. , Shah, Vijay H. , Bataller, Ramón , Bataller, Ramon A , Simonetto, Douglas A , Vargas, Victor , Richardson, Taylor, Sarin, Shiv Kumar , Singal, Ashwani K. , Cabezas, Joaquín

Mayo Clinic

Liver Transplantation | August 30, 2018 | Volume: 24 | Issue: 12 | Pages: 1655-1664

10.1002/lt.25328 | PMID 30153377 Get It

Abstract Identifying patients at high risk for acute kidney injury (AKI) during hospitalization among patients admitted with severe alcoholic hepatitis (AH) is an unmet clinical need. We performed a multicentric prospective cohort study using data from 4 different cohorts on well‐characterized patients hospitalized with severe AH. Data collected on 773 AH patients from 4 cohorts across the globe were randomly split into test (n = 390) and validation (n = 383) cohorts. We found that 32% of the patients developed inpatient AKI in the test cohort. Approximately 60% of patients met criteria for systemic inflammatory response syndrome (SIRS) at admission. Hepatic encephalopathy, SIRS, and Model for End‐Stage Liver Disease score at admission predicted inpatient AKI with odds ratios of 3.86, 2.24, and 1.14, respectively. The AKI risk score developed using these predictors stratified risk of inpatient AKI to low (score <3), moderate (3‐4), and high (>4). These findings were replicated in the validation cohort. In the whole study cohort, patients with AKI had a lower 90‐day survival (53% versus 77%; P < 0.001). Those with AKI risk score of >4 had significantly lower 90‐day survival as compared with those with risk scores between 3 and 4 and <3 (47% versus 68% versus 88%; P < 0.001). In conclusion, AKI occurs frequently in AH patients and negatively impacts short‐term mortality. The AKI risk score is useful in identifying patients at high risk for inpatient AKI and may be useful for developing new therapeutic strategies to prevent AKI in patients with AH.